| |
| |
| Catalent to Acquire Cell Therapy Manufacturing Assets from Bone Therapeutics |
|
|
|
|
|
| Catalent has signed an agreement with Bone Therapeutics to acquire its facility and manufacturing assets in Gosselies, Belgium.
The facility, which is next to Catalent’s existing cell therapy site, will allow Catalent to expand its industry-leading cell therapy capabilities and advanced clinical and commercial supply, and create an integrated European center of excellence in cell therapy. |
|
|
| | |
|
|
| |
| |
| Catalent Launches OptiGel® DR, a Delayed/Enteric Release Softgel
The OptiGel® DR technology allows softgel capsules to be formed by combining pectin, a naturally derived polysaccharide, with gelatin, eliminating the need for a separate capsule coating step. |
|
|
|
|
|
| |
| |
| Catalent is Proud to Support Many High-Profile COVID-19 Programs
Catalent has been awarded more than 60 COVID-19-related compounds including antivirals, vaccines, diagnostics and treatments across our biologics, gene therapy, oral technologies, softgel and clinical supply businesses. |
|
|
|
|
|
| |
| |
| CBS News Interviews Karen Flynn, President, Biologics and Chief Commercial Officer, Catalent
In the interview, on CBS News “60 Minutes”, Ms. Flynn discusses Catalent's role in the vaccine manufacturing process and how various supply chain partners are working together to deliver COVID-19 vaccines at warp speed. |
|
|
|
|
|
| |
| |
| Catalent and BrainStorm Cell Therapeutics Partner for the Manufacture of NurOwn®
NurOwn® is BrainStorm’s autologous cellular therapy being investigated for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or motor neuron disease. |
|
|
|
|
|
| |
| |
| |
| |
| |
| Catalent Boosts Supply Chain Transparency in Response to COVID-19 Manufacturing Urgency
During a fireside chat at the virtual BIO Investors Forum, Karen Flynn, President, Biologics and Chief Commercial Officer, Catalent, discussed the company’s supply chain response to COVID-19: “We need open dialog about industry needs, up and down the supply chain for planning purposes.” |
|
|
|
|
|
| |
| |
| Fierce Pharma Interview: Oral Drug Development Scale-up
In an interview with Fierce Life Sciences, Jeremy Trochu, Vice President and General Manager of Pharmaceutical Development Services at Catalent, discusses the key factors to consider when planning the scale-up of an oral drug development program. |
|
|
|
|
|
| |
| |
| DCAT Women Leaders in Pharma Interview Series
Karen Flynn, President, Biologics and Chief Commercial Officer at Catalent was recently interviewed in DCAT's Alliance for Industry Women Leaders in Pharma series. She gives advice on leadership, industry insights and why she chose a career in science. |
|
|
|
|
|
| |
| Join Our Experts at Live Virtual Events to Hear the Latest on COVID-19 and Technology Development Programs |
|
|
|
|
|
| Virtual Conference | Manufacturing Chemist Live | November 10-11
Christopher Harrison, Director of Manufacturing Operations, Catalent will discuss some of the key issues to consider when planning for the scale-up of a small molecule development program, with a focus on highly potent drugs.
Virtual Congress | 2020 Bio/Pharma Virtual Congress | November 11
Lisa Caralli, Director, Science and Technology, Catalent will discuss data-driven approaches to early development including PBPK modeling, parallel formulation screening, API-sparing techniques and optimal early dosing strategies that will help avoid development pitfalls and de-risk path to clinic.
Webinar | Discover the Latest Funding, Drug Development and Clinical Solutions Strategies | November 11
This webcast is specifically designed for pharmaceutical and biotech consultants, and early stage development partners. Experts in early drug development will present their insights to help your clients get their molecules from preclinical to Phase 1 studies. |
|
|
|
|
|
| |
| |
| A Catalyst in Drug Development | | William Wei Lim Chin, Ph.D. Global Scientific Affairs Manager, Science & Technology, Eberbach, Germany |
|
|
|
|
|
| Dr. Chin is a biomedical and pharmaceutical scientist, he received his doctorate degree from the Department of Pharmacy at the National University of Singapore. In his current role at Catalent’s Eberbach, Germany, facility he is responsible for developing scientific content, designing tactics for scientific communications, ensuring technical accuracy and validity of key messaging across all business units. Access Dr. Chin’s extensive research and peer-reviewed articles on oral delivery, pediatric drug formulation and more. |
|
|
| | |
|
|
| |
| |
| |
| Biologics
Webinar: “Disease Prevention & Control Summit 2020: Manufacturing Drugs & Vaccines Panels” - Originally presented at the virtual Disease Prevention & Control Summit, this panel-style webinar features experts from AstraZeneca, Translate Bio, and Catalent Biologics. Participants discussed the risks and challenges associated with pandemic drug manufacture. Webinar: “The Faster Path to Self-Administration: Moving from Pre-Filled Syringe to Auto-Injector” – Experts from Ypsomed and Catalent Biologics discuss strategies for integrated pre-filled syringe manufacturing and auto-injector assembly to accelerate timelines and more. Article: “Drug Product Process Development: Ensuring a Consistent, High-quality Biologic” - In this Q&A, Dhaval Patel, Manager, Manufacturing Technology, Drug Product, Catalent Biologics shares perspectives on overcoming process development challenges with new biological entities and biosimilars, and what to expect from the development and manufacturing partner during the drug product process development phase. |
|
|
| | |
|
|
| |
| |
| |
| |
| |
| Catalent ignites the development of their future leaders by continuously investing in their employees and creating an innovative environment to advance their potential. We are growing rapidly across sites in Bloomington, Indiana, Madison, Wisconsin, Winchester, Kentucky, and more.
Visit www.catalent.com/careers for more information. |
|
|
| | |
|
|
| |
| Every brand has a challenge. We have a solution. | | | | or call +1 877 891 9609 to speak with one of our experts today! | | |
|
|
|
|
|
| |
| To unsubscribe or manage your subscriptions, please click here.
For more information call +1-866-720-3148 or in Europe 00800 88 55 6178, email us at sales@catalent.com, or visit our website www.catalent.com. And to learn more about Career opportunities across our global network, visit www.catalent.com/careers. Catalent Pharma Solutions respects your privacy. Links to third party sites are provided as a convenience only. Catalent makes no representation or warranty about the technology, security or any content available at these sites. Links are not intended to imply Catalent's affiliation or endorsement of the website, its owner(s) or the content. © 2020, Catalent Pharma Solutions, Inc. 14 Schoolhouse Road, Somerset, NJ 08873. All rights reserved. |
|
|
|
|
|
| |
